[Pathogenesis of insulin-dependent (type I) diabetes mellitus].
Weber
B
B
D000293:Adolescent; D000328:Adult; D000818:Animals; D000954:Antigens, Surface / Q000276:immunology; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001323:Autoantibodies / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D002648:Child; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D003922:Diabetes Mellitus, Type 1 / Q000209:etiology / Q000235:genetics / Q000276:immunology / Q000503:physiopathology*; D006680:HLA Antigens / Q000235:genetics; D015235:HLA-B Antigens; D015803:HLA-DR3 Antigen; D015804:HLA-DR4 Antigen; D000949:Histocompatibility Antigens Class II / Q000235:genetics; D006801:Humans; D007111:Immunity, Cellular; D007116:Immunization, Passive; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000276:immunology; D051379:Mice; D008815:Mice, Inbred Strains; D010956:Plasmapheresis; D012621:Seasons; D013601:T-Lymphocytes / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D014777:Virus Diseases / Q000150:complications
D000954:Antigens, Surface; D000961:Antilymphocyte Serum; D001323:Autoantibodies; D006680:HLA Antigens; D015235:HLA-B Antigens; D015803:HLA-DR3 Antigen; D015804:HLA-DR4 Antigen; D000949:Histocompatibility Antigens Class II; D007166:Immunosuppressive Agents; C024211:islet cell antibody
Pathogenese des Insulinabhängigen (Typ I) Diabetes mellitus.